which anticoagulant inhibits blood coagulation by selectively blocking the active site of factor xa
Rivaroxaban is an oral factor Xa inhibitor that inhibits coagulation by selectively blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activity. It is indicated for treatment of DVT or PE, and to reduce risk of recurrent DVT and PE following initial treatment.